By Justin Petrone

Cytoo will use the proceeds from its most recent round of financing to fund several R&D projects and expand its marketing activities, with the hope of attracting more interest from pharmaceutical customers, according to its CEO.

Francois Chatelain told BioArray News this week that the developer of micropattern array technology for cell-based assays raised the $10 million in series C financing to "aggressively do R&D and innovation" and to "beef up" its marketing efforts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.